99b069de-d4dd-4c9b-89c3-8b50a59ea334
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.570
- OXIDATIVE_PHOSPHORYLATION+0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.430
- TNFA_SIGNALING_VIA_NFKB+0.420
- ALLOGRAFT_REJECTION+0.340
- IL6_JAK_STAT3_SIGNALING+0.320
- APOPTOSIS+0.310
- DNA_REPAIR+0.300
- GLYCOLYSIS+0.250
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.410
- WNT_BETA_CATENIN_SIGNALING-0.390
- BILE_ACID_METABOLISM-0.340
- MYOGENESIS-0.190
- NOTCH_SIGNALING-0.140
- KRAS_SIGNALING_DN-0.130
- UV_RESPONSE_DN-0.120
- APICAL_SURFACE-0.090
- PANCREAS_BETA_CELLS-0.090
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8f1213be-da41-4cd6-97b2-f9fce1ea00ff | — | — | 0.875 |
| 2 | f5174c29-918d-4ad9-bd44-c94463396414 | — | — | 0.874 |
| 3 | TCGA-O2-A52Q-01A-11R-A26W-07 | — | cohortA1 | 0.872 |
| 4 | B8AED170-C88C-4A86-8377-93B5D14AB334 | — | — | 0.850 |
| 5 | a0fad25f-74d8-42f1-8e47-4d56c091e000 | — | — | 0.846 |
| 6 | C3N-02087 | — | cohortA1 | 0.826 |
| 7 | X16125ffc.4138.408e.9573.cd6c960504cf | — | cohortA1 | 0.825 |
| 8 | BS_GJNCYABP | ATRT | — | 0.825 |
| 9 | f66a9fee-f63a-4398-b242-9c065bbe213d | — | — | 0.823 |
| 10 | 9E5B5D00-45A2-48A9-9F57-0B4AAE9E4E25 | — | — | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.570 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.430 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.420 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.190 | Idelalisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |